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Introduction
Vitamin K antagonists (VKAs) provide effective antico-
agulation and have been the mainstay of anticoagulation 
therapy for more than 50 years. VKAs are mostly used as 
long-term anticoagulant therapy, including for the preven-
tion of stroke in patients with atrial fibrillation (AF) and 
the treatment of venous thromboembolism (VTE). War-
farin currently remains the most frequently prescribed 
oral anticoagulant (OAC) for these indications, even with 
the approval within the past 5  years of four new agents, 
namely the direct factor Xa inhibitors apixaban, edoxaban 
and rivaroxaban and the direct thrombin inhibitor dabi-
gatran [collectively known as novel/non-VKA/direct OACs 
(DOACs)].
On average, patients with AF have a five-fold higher risk 
of stroke than patients without AF—irrespective of whether 
they have paroxysmal or chronic AF [123]. AF-related 
strokes are associated with an approximately 50% increased 
risk of disability and a 60% increased risk of death at 
3 months compared with strokes of other aetiologies [83]. 
The number of strokes caused by AF-related thrombo-
embolisms may be even higher than currently thought 
because data from recent studies have shown that crypto-
genic strokes (i.e. those without a well-defined aetiology) 
account for approximately 30% of ischaemic strokes [112]. 
Evidence suggests that up to 30% of patients with crypto-
genic stroke may have AF [54, 110]. Therefore, effective 
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anticoagulation is vital for the long-term management of 
patients with AF at an intermediate or high risk of stroke 
[27, 125]. VKAs reduce the rate of stroke by approximately 
60% [65], whereas antiplatelet therapy is much less effica-
cious (reducing the event rate by approximately 20%) and 
has almost the same bleeding risk as oral anticoagulation 
therapy [2, 85]. Despite guideline recommendations and 
clear evidence that oral anticoagulation therapy is indicated 
in patients with AF and who have a CHA2DS2-VASc score 
of ≥1, several studies report that, on average, only 60% of 
eligible patients receive anticoagulation therapy.
The pharmacological characteristics of VKAs, particu-
larly their narrow therapeutic window combined with many 
drug–drug and drug–food interactions, necessitate regular 
coagulation monitoring and dose adjustments [3, 5]. An 
important measure for anticoagulation control with VKAs 
is the percentage of time a patient spends within the target 
therapeutic range [i.e. international normalized ratio (INR) 
of 2.0–3.0]. A number of studies have shown that INR con-
trol of VKA therapy is suboptimal in routine clinical prac-
tice and, in general, patients spend approximately 40% of 
time outside the recommended INR range. Poor INR con-
trol is associated with increased risk of stroke (INR <2.0) 
and bleeding (INR >3.0) [88, 122]. Real-life evidence 
demonstrates that time in therapeutic range (TTR) also var-
ies depending on care setting, such as whether patients are 
managed by a dedicated anticoagulation clinic or by their 
general practitioner, cardiologist or neurologist [91].
DOACs have been developed to overcome the limita-
tions of VKA therapy. These agents are now approved in 
many countries worldwide for the prevention of stroke and 
systemic embolism in patients with non-valvular AF, as 
well as for other thromboembolic disorders (Table 1) based 
on data from phase III, randomized clinical trials [11, 20, 
22, 38]. DOACs were at least as good as, if not superior 
to, warfarin in terms of efficacy for the prevention of stroke 
in patients with non-valvular AF and also offered a better 
safety profile (all four major trials consistently indicated 
reduced rates of intracranial and fatal or life-threatening 
bleeding compared with the respective warfarin arm) 
[32, 52, 58, 102, 109]. Real-world evidence of DOACs is 
accumulating, and available data support the findings of 
the phase III clinical studies (for example [13, 15, 16, 18, 
26, 117, 121]). In general, current guidelines recommend 
DOACs in preference to VKAs [27, 114] or as an alterna-
tive to VKAs [74, 94] for prevention of stroke or systemic 
embolism in patients with non-valvular AF. However, 
VKAs are still regarded as the ‘gold standard’ by some 
physicians and continue to be prescribed to many patients, 
including those who have had difficulties maintaining their 
INR within the target therapeutic range [48, 88].
This article highlights real and perceived implications 
of VKAs for the prevention of stroke in patients with 
non-valvular AF, with specific reference to their strengths 
and weaknesses compared with DOACs. Furthermore, 
it provides practical guidance on which patients should 
be switched from VKA to DOAC therapy, which patients 
should stay on VKA therapy and which DOAC should be 
given to which patient. Finally, this paper discusses the 
most suitable overall approach to reducing the burden of 
AF-related stroke.
Characteristics of vitamin K antagonist therapy: 
why it works and areas of inadequacy
The pharmacological characteristics of different VKAs, 
such as warfarin, phenprocoumon and acenocoumarol 
(Table 2) are associated with several advantages and practi-
cal limitations [3, 44].
VKAs have several inherent advantageous character-
istics. They are not eliminated by the kidneys and, there-
fore, can be used in patients with severe renal impairment. 
Moreover, the need for regular INR monitoring encourages 
regular physician–patient contact despite being inconven-
ient and imposing additional costs. However, although reg-
ular physician visits may be beneficial from a medical point 
of view, poor medication adherence is usually attributable 
to multiple, interlinked factors and there is no evidence that 
regular physician visits alone can increase patient adher-
ence [23].
In the case of a missed VKA dose, patients are at less 
immediate risk of a thrombotic event than patients missing 
a dose of DOAC, and non-adherent patients may benefit 
from the slow offset of action. However, (similar to initia-
tion of therapy) reinitiating therapy after missing several 
doses of a VKA may actually result in a profound pro-
thrombotic state [3, 8]. Many physicians are highly famil-
iar with the management and the responsible use of VKAs. 
Moreover, drug costs of VKAs are significantly lower than 
those of DOACs. Therefore, physicians may be hesitant to 
prescribe any of the DOACs.
On the downside, VKAs have an indirect anticoagulant 
mechanism of action, impairing the synthesis of several 
vitamin K-dependent coagulation factors (Fig.  1), which 
results in a slow onset and offset of the anticoagulant effect. 
On initiation, VKAs are inherently prothrombotic (a fact 
often overlooked by physicians) because they inhibit the 
natural anticoagulant proteins C and S faster than inhibiting 
the coagulation factors X, IX, VII and II: this creates a tem-
porary imbalance in favour of procoagulation factors [3, 8]. 
In a large case-control study in more than 70,000 patients 
with AF, warfarin was associated with a 71% increased 
risk of stroke in the first 30  days of treatment compared 
with longer periods of treatment [8]. Hence, bridging 
therapy with a fast-acting, parenteral anticoagulant (e.g. 
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enoxaparin, unfractionated heparin) is necessary on ini-
tiation of VKA therapy. For surgery or other interventional 
procedures, the slow offset of action may delay the pro-
cedure. Furthermore, bridging therapy with a fast-acting 
anticoagulant may also be necessary after the procedure to 
ensure efficient anticoagulation.
VKAs have a narrow therapeutic range (Fig.  2) and, 
therefore, require regular coagulation monitoring and 
dose adjustments in some patients to keep the anticoagula-
tion intensity within the therapeutic range [3]. Data show 
that patients on VKAs are effectively anticoagulated only 
approximately 60% of the time, or even less in some coun-
tries [6, 88]. Keeping patients within the target therapeutic 
range is further complicated by VKAs having multiple food 
and drugs interactions [3]. These factors can have a signifi-
cant impact on patients’ daily lives, such as considerable 
time spent in the clinic for coagulation monitoring and die-
tary restrictions, all of which may reduce patients’ quality 
of life [3]. Furthermore, routine anticoagulation monitoring 
confers additional costs: the cost of the test itself, travel, 
nurse visits, missed work and the increased workload for 
physicians and other healthcare staff [1].
Characteristics of the direct oral anticoagulants: 
what renders them so attractive and what are 
their limitations?
The pharmacological characteristics of DOACs provide 
many practical advantages over VKA therapy (Table  2). 
Direct targeting of factor Xa or thrombin allows for a much 
faster effective anticoagulation effect—within 0.5–4 h [51, 
Table 1  Indications and dosing regimen of DOACs in the EU [11, 20, 22, 38]
ACS acute coronary syndrome, AF atrial fibrillation, bid twice daily, DOAC direct oral anticoagulant, DVT deep-vein thrombosis, od once daily, 
PE pulmonary embolism, VTE venous thromboembolism
a Not recommended in patients with CrCl <15 mL/min
b Contraindicated in patients with CrCl <30 mL/min
c Started with a half dose 1–4 h after completion of surgery followed by full doses from the next day onwards; reduced dose of 150 mg od (taken 
as two tablets of 75 mg) in patients with one or more of the following: CrCl 30–50 mL/min; receiving concomitant verapamil, amiodarone or 
quinidine; aged ≥75 years
d Reduced dose of 30 mg od in patients with non-valvular AF or VTE plus one or more of the following clinical factors: CrCl 15–50 mL/min; 
low body weight ≤60 kg; concomitant use of the following P-glycoprotein inhibitors: cyclosporine, dronedarone, erythromycin or ketoconazole
e After the initial dosing period of 15 mg bid for 3 weeks, a reduced dose of 15 mg od should be considered if the patient’s assessed risk for 
bleeding outweighs the risk for recurrent VTE
f Reduced dose of 110  mg bid in patients with non-valvular AF or VTE aged ≥80  years or receiving concomitant verapamil; consider this 
reduced dose based on individual assessment of thromboembolic risk and bleeding risk in: patients aged 75–80 years, patients with CrCl 
30–49 mL/min; patients with gastritis, oesophagitis or gastroesophageal reflux, and other patients at increased risk of bleeding
g Reduced dose of 2.5 mg bid in patients with non-valvular AF and serum creatinine ≥1.5 mg/dL (133 µmol/L) plus age ≥80 years and/or body 
weight ≤60 kg
h Reduced dose of 15 mg od in patients with non-valvular AF and CrCl 15–50 mL/min
Factor Xa inhibitor Direct thrombin inhibitor
Apixabana Edoxabana Rivaroxabana Dabigatranb
Prevention of VTE after 
elective hip or knee 
replacement surgery
2.5 mg bid (Not approved) 10 mg od 220 mg od (as two tablets of 
110 mg)c
Treatment of DVT/PE and 
prevention of recurrent 
DVT/PE
10 mg bid for 7 days 
followed by 5 mg bid; 
2.5 mg bid for prevention 
of recurrence (following 
6 months of treatment)
60 mg od (following paren-
teral anticoagulant for at 
least 5 days)d
15 mg bid for 3 weeks 
followed by 20 mg 
ode
150 mg bid (following par-
enteral anticoagulant for at 
least 5 days)f
Prevention of stroke and 
systemic embolism in 
patients with non-valvular 
AF with ≥1 risk factors
5 mg bidg 60 mg odd 20 mg odh 150 mg bidf
Prevention of atherothrom-
botic events in patients 
with elevated cardiac 
biomarkers after an ACS 
in combination with anti-
platelet therapy
(Not approved) (Not approved) 2.5 mg bid (Not approved)
368 A. Zirlik, C. Bode 
1 3
62, 89, 92]—and a faster offset of action as opposed to the 
indirect mode of action via multiple coagulation factors 
as in the case of VKAs (Fig. 2). Moreover, the kinetics of 
DOACs (e.g. rivaroxaban [78]) closely mimic those of the 
low-molecular-weight heparin enoxaparin. Therefore, in 
contrast to VKAs, bridging with a parenteral anticoagulant 
is not necessary with the DOACs [66]. DOACs also have 
a much shorter half-life compared with VKAs, making 
bridging to interventions or surgery obsolete [67].
DOACs have predictable pharmacokinetics and pharma-
codynamics and a lower potential for food and drug inter-
actions [11, 20, 22, 38]. These agents can, therefore, be 
given at fixed dosing schedules without the need for dietary 
restrictions or routine coagulation monitoring. However, 
the lack of the requirement for routine monitoring does not 
negate the need for regular physician–patient contact and 
patients should schedule regular visits. Although the fre-
quency of these visits should be determined by bleeding 
risk (HAS-BLED score), age and renal function, patients 
are recommended to return every 3 months for a review of 
their treatment [67]. Measurement of the anticoagulation 
effect and/or drug levels may be helpful in certain clinical 
circumstances, such as in the event of suspected overdose, 
during bleeding events, prior to urgent surgery, in patients 
with deteriorating renal function or when determining the 
use of thrombolysis.
Unlike VKAs, DOACs are eliminated renally, albeit at 
different rates; renal impairment affects exposure and the 
associated risk of bleeding. Renal clearance of the absorbed 
active drug is approximately 27% for apixaban [22], 35% 
for rivaroxaban [92], 50% for edoxaban [38] and >80% 
for dabigatran [46]. Based on these characteristics, apixa-
ban, edoxaban and rivaroxaban are not recommended in 
patients with AF and who have creatinine clearance (CrCl) 
Table 2  Overview of pharmacological characteristics of direct oral anticoagulants and vitamin K antagonists [3, 59, 66, 71, 106, 119]
CYP cytochrome P450, NR not reported, P-gp P-glycoprotein, R- (R)-enantiomer, S- (S)-enantiomer, tmax time to reach maximal plasma concen-
tration
a Rivaroxaban 20 mg: 66% under fasting conditions (mean area under the plasma concentration–time curve increased by 39% when given with 
food)
b The 15 and 20 mg doses of rivaroxaban should be taken with food to enhance their absorption
Characteristics Dabigatran Apixaban Rivaroxaban Edoxaban Warfarin Acenocoumarol Phenprocoumon
Target Factor II Factor Xa Factor Xa Factor Xa Factors II, VII, IX 
and X, protein S 
and C
Factors II, VII, IX 
and X, protein S 
and C
Factors II, VII, IX and 
X, protein S and C
Oral bioavailability 
(%)
3–7 50 80–100a 62 ~100 S-Acc: 60
R-Acc: ~100
~100
tmax (h) 0.5–2 1–4 2–4 1–2 1.5 1–4 1–4






Protein binding (%) 34–35 87 92–95 55 >99 >98 >99
Renal clearance of 
absorbed active 
drug (%)
80 27 33 50 80 65 65
CYP substrate No 3A4/5 3A4, 2J2 3A4/5 2C9 2C9 2C9
P-gp substrate Yes Yes Yes Yes No No No
Food interaction No No Nob NR Yes Yes Yes
Routine coagulation 
monitoring required
No No No No Yes Yes Yes
Fig. 1  Coagulation cascade with sites of inhibitions for VKAs and 
direct oral anticoagulants indicated. Coagulation factors are indicated 
using their factor numbers in roman numerals, with ‘a’ indicating an 
active factor. TF tissue factor, VKA vitamin K antagonist
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<15 mL/min [11, 22, 38] and dabigatran is contraindicated 
in patients with CrCl <30  mL/min [20]. Furthermore, 
edoxaban should be used with caution in patients with high 
CrCl because of reduced efficacy [38]; In the US, edoxaban 
should not be used in patients with CrCl >95 mL/min [39].
Vitamin K antagonists: performance in real‑world 
practice
Time in therapeutic range and real‑world effectiveness 
and safety
VKAs can only provide clinical benefit if the antico-
agulation effect is kept within the therapeutic range (INR 
2.0–3.0); poor INR control can lead to an increased risk of 
thromboembolism (INR <2.0) or bleeding (INR >3.0) [5]. 
TTR during VKA therapy is higher during controlled clini-
cal studies than in daily practice, owing to their strict study 
protocols and the regular follow-up with patients. Moreo-
ver, TTR control in daily clinical practice is also dependent 
on whether the patient is managed by a dedicated antico-
agulation clinic or elsewhere, such as by a general practi-
tioner, cardiologist or neurologist [91]. The rate of fatal and 
major bleeding events was low (0.25 and 1.1% per year, 
respectively) in patients whose anticoagulation with warfa-
rin was managed by an anticoagulation clinic achieving a 
median TTR of 68% [91, 101].
The inability to maintain TTR is well reported: in the 
Registry of Canadian Stroke Network, 74% of patients 
with known AF who were taking warfarin at the time of 
ischaemic stroke had sub-therapeutic anticoagulation [53]. 
Additional evidence emphasizes that stroke prevention with 
a VKA is effective in patients who have a good individual 
mean TTR (>75%) [91]. Data from the GARFIELD-AF 
registry indicate that only 29% of VKA-treated patients 
had good anticoagulation control, defined as a TTR ≥70%, 
and that heavy alcohol use was associated with poor anti-
coagulation control (TTR ≤60%) [118]. Patients with poor 
control had a significantly higher risk of death [hazard ratio 
2.87; 95% confidence interval (CI) 1.97–4.19] and stroke/
systemic embolism (hazard ratio 1.98, 95% CI 1.13–3.47) 
than those with a TTR >60% [118].
Data collected outside of anticoagulation clinics (and, 
therefore, most likely in patients with suboptimal antico-
agulation control) suggest that real-world effectiveness fails 
to reproduce efficacy data for VKAs seen in clinical stud-
ies. However, warfarin has been shown to prevent stroke 
and systemic embolism more effectively than placebo or 
acetylsalicylic acid. A large meta-analysis of clinical study 
data demonstrated a 62% reduction in the risk of stroke 
and systemic embolism with warfarin therapy compared 
with placebo/acetylsalicylic acid therapy [64]. A real-world 
Canadian study in patients with AF showed that warfarin-
treated outpatients had a significantly lower risk of stroke 
compared with patients who did not receive any antithrom-
botic treatment (risk ratio 0.31) [29]. The risk of bleeding 
is much higher in clinical practice compared with the rates 
reported in clinical studies. A large cohort study in 125,195 
patients with AF demonstrated a high risk of haemorrhage 
during the first 30 days of warfarin therapy (11.8% per 
year): considerably higher than the rates of 1–3% reported 
in randomized controlled trials [55]. In the GARFIELD-AF 
registry, treatment at an anticoagulation clinic or thrombo-
sis centre was associated with a better TTR compared with 
other settings (proportion of patients with TTR >60%: 57.1 
vs. 46.2%) [118].
There are efforts to simplify the management of VKAs 
by way of patient self-testing and self-management. Initial 


































































Fig. 2  Observed and predicted risk of a ischaemic stroke and b 
haemorrhagic stroke according to INR [5]. Reprinted from European 
Journal of Internal Medicine, Vol 20, Amouyel P, Mismetti P, Lang-
kilde LK, et al. INR variability in atrial fibrillation: A risk model for 
cerebrovascular events. Pages 63–69, Copyright 2009, with permis-
sions from Elsevier
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patients in these trials had a high level of education, which 
is not necessarily a true representation of all patients 
encountered in daily clinical practice. Finally, studies try-
ing to optimize the benefit–risk ratio of VKAs by lowering 
the INR range to 1.5–2.5 failed, with inferior efficacies but 
similar bleeding compared with standard-dose VKA ther-
apy [103].
Patient preference and compliance to vitamin K 
antagonist therapy
Limitations and inconveniences that both physicians and 
patients associate with VKA therapy are contributing 
to their under-prescription in patients with high risk of 
stroke and systemic embolism. In the GARFIELD-AF reg-
istry, 38.0% of patients with a CHADS2 score ≥2 did not 
receive anticoagulant therapy; 7.2% of patients with AF 
and CHADS2 ≥2 had refused treatment for various reasons, 
including inconvenience of regular blood tests, dietary 
restrictions, bleeding risk and an under-appreciation or lack 
of knowledge regarding the risk of stroke.
As well as being unwilling to start VKA therapy, many 
patients with AF who are initiated on VKA therapy discon-
tinue or are non-adherent [47, 56, 77, 98]. For example, of 
125,195 patients newly diagnosed with AF in Canada from 
1997 to 2008, 9% did not collect their second prescription 
of warfarin within the first half year and 32% discontinued 
therapy within 1 year, rising to 43% at 2 years and 61% at 
5 years [56]. Similarly, in a US study, more than one in four 
new warfarin starters discontinued therapy within a year 
[47]. In another study, 40% of patients were non-adherent 
to VKA therapy (>20% of days with missed doses or >10% 
of days where extra doses were taken in addition to the pre-
scribed dose), and this percentage was significantly associ-
ated with poor anticoagulation control [77].
Underuse and inappropriate use of anticoagulation 
therapies
Large registries published between 2005 and 2009 by the 
European Heart Survey, the German Competence NETwork 
on AF (AFNET) and the Canadian Stroke Network suggest 
that 30–60% of patients with AF who are eligible accord-
ing to guidelines are not prescribed anticoagulation ther-
apy [53, 93, 97]. In the Registry of Canadian Stroke Net-
work, only 10% of patients with acute stroke with known 
AF were therapeutically anticoagulated at time of hospi-
tal admission [53]. Underuse of anticoagulation in these 
patients had unfavourable implications: approximately 
80% of the resulting strokes were disabling or fatal [53]. 
The global GARFIELD-AF registry (2009–2011) found 
that 34% of patients with a CHADS2 score ≥2 received 
antiplatelet therapy [76]. Of patients with a CHADS2 score 
≥2 who received anticoagulation therapy, 62% received a 
VKA. In addition, 43% of patients with a CHADS2 score of 
0 received anticoagulation therapy.
Taken together, there appears to be underuse of anti-
coagulation therapy in patients at moderate to high risk 
of stroke and systemic embolism and overuse in patients 
at low risk—demonstrating that, in real-life practice, pre-
scribed therapy is often not based on evidence-based risk 
schemes and guidelines [76]. In almost half of the cases 
(48.3%) in which VKA therapy was not prescribed, this 
was the physician’s choice and not based on guidelines 
or contraindications to therapy; the physician’s reasons 
included concerns over bleeding risk (7.4%), concerns over 
the risk of falling (6.5%), concerns over patient compliance 
(5.3%) and perceived low risk of stroke (4.1%). Many of 
the concerns given as reasons for not prescribing VKA are 
not supported by actual data. For example, a prospective 
study in patients on OACs at high risk of falls did not have 
a significantly increased risk of major bleeding events [40].
Poor TTR in everyday clinical practice, coupled with 
low rates of adherence or high discontinuation rates, and 
a general underuse of VKA therapy supports the need for 
alternative oral anticoagulation options that are easier to 
manage and more convenient than VKA therapy. In the 
next sections, we review clinical studies and real-world 
data, with the practical advantages associated with DOAC 
therapy compared against the aforementioned limitations 
associated with VKAs.
Vitamin K antagonists vs. direct oral 
anticoagulants: outcomes of phase III studies 
and real‑life evidence
Efficacy and safety
Results from phase III trials of DOACs, with a wide range 
of patients with AF worldwide, showed that all DOACs 
are at least as effective as warfarin, with similar or lower 
rates of major bleeding [32, 34, 52, 58, 102]. Importantly, 
a direct, head-to-head comparison of these studies is not 
feasible because the study designs and study populations 
were different. In a meta-analysis of all four DOACs in 
phase III trials for stroke/systemic embolism prevention in 
patients with AF vs. warfarin, these agents reduced the risk 
of haemorrhagic stroke by 51% and the risk of intracranial 
haemorrhage by 52% [109].This favourable benefit–risk 
profile extends to many subgroups and ethnicities including 
the Asian population in which the rate of intracranial bleed-
ing is reduced by up to 80% (as reviewed elsewhere [31, 
72, 73]). Conversely, the risk of gastrointestinal bleeding 
was 25% higher with DOACs than with warfarin, owing 
to bleeding events with dabigatran (150  mg twice daily), 
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edoxaban (60  mg once daily) and rivaroxaban (20  mg) 
(Tables 3, 4) [32–34, 43, 52, 58, 102, 109].
There are several studies comparing real-life effective-
ness and safety of VKAs with DOACs (mainly dabigatran 
or rivaroxaban vs. warfarin; data for apixaban are emerg-
ing; data for edoxaban are currently lacking; Table  S1 in 
the electronic supplementary material). Published studies 
to date demonstrate similar or improved effectiveness with 
DOACs compared with VKAs (Table S1 in the electronic 
supplementary material). Recent publications showed dis-
crepancies in real-world effectiveness and safety outcomes 
with DOACs compared with previously published database 
analyses or compared with phase III clinical trial results 
(Table 3).
Real-life evidence from the international, non-interven-
tional, observational phase IV XANTUS study demon-
strates that rates of stroke and major bleeding were low in 
patients receiving rivaroxaban [26]. Data from the Dresden 
NOAC Registry suggest that rates of major bleeding may 
be lower with rivaroxaban, apixaban and dabigatran ther-
apy compared with VKA therapy [13, 16, 18, 90]. Moreo-
ver, these data show that real-life rates of major bleeding 
with rivaroxaban were similar (Dresden NOAC Registry 
[16, 102]) or lower (XANTUS [26]) compared with find-
ings from ROCKET AF [16, 102]. Other observational 
studies mainly demonstrate that rivaroxaban and dabigatran 
have similar or reduced rates of major bleeding compared 
with VKAs, and reflect the decreased incidence of intracra-
nial haemorrhage and increased incidence of gastrointesti-
nal bleeding [30].
Adherence, persistence and discontinuation
Adherence is defined as the extent to which the patient acts 
in accordance with the prescribed interval and dose of the 
dosing regimen and can also be defined as the percent of 
doses taken as prescribed [36]. Persistence measures the 
duration of drug therapy during which the patient takes 
medication without exceeding the permissible gap (usually 
60 days). Two retrospective US database analyses showed 
that patients with AF were significantly more persistent 
with rivaroxaban than with warfarin, reporting patient 
persistence with warfarin dropping to <70% at 6  months 
of therapy [80, 95]. A retrospective US database analysis 
demonstrated that persistence was higher with dabigatran 
than with warfarin at 6  months (72 vs. 53%) and 1  year 
(63 vs. 39%) [126]. This study also showed that patients 
with a low-to-moderate stroke risk (CHADS2 <2) or with 
a higher bleeding risk (HEMORR2HAGES >3) were more 
likely to discontinue treatment than patients with a high 
stroke risk or lower bleeding risk [126]. When comparing 
persistence or adherence among DOACs, two retrospective 
analyses of different US databases demonstrated that use of 
the once-daily medication rivaroxaban was associated with 
Table 3  Main efficacy and safety results from the phase III clinical trials of the direct oral anticoagulants approved for prevention of stroke in 
patients with non-valvular atrial fibrillation
Values in bold indicate a statistically significant difference between the direct oral anticoagulant and warfarin
GI gastrointestinal, ICH intracranial haemorrhage, NR not reported, NMCR non-major clinically relevant, SE systemic embolism
a Intention-to-treat analysis
b Data with additional events as per [34] or [33] or [43]
c Primary efficacy endpoint in ENGAGE-AF was time to adjudicated stroke or systemic embolic event
d Primary safety outcome in RE-LY and ARISTOTLE
e Major or minor bleeding (minor bleeding was any bleeding not considered to be a major bleeding event)











110 mg 150 mg 30 mg 60 mg
Efficacy outcomes (% per year)
 Stroke or SEa 1.54 vs. 1.72b 1.12 vs. 1.72b 2.1 vs. 2.4 1.27 vs. 1.60 1.61 vs. 1.50c 1.18 vs. 1.50c
 All-cause mortality 3.75 vs. 4.13 3.64 vs. 4.13 1.9 vs. 2.2 3.52 vs. 3.94 3.80 vs. 4.35 3.99 vs. 4.35
 Myocardial infarction 0.82 vs. 0.64b 0.81 vs. 0.64b 0.9 vs. 1.1 0.53 vs. 0.61 0.89 vs. 0.75 0.70 vs. 0.75
Safety outcomes (% per year)
 Major bleeding 2.92 vs. 3.61b,d 3.40 vs. 3.61b,d 3.6 vs. 3.4 2.13 vs. 3.09d 1.61 vs. 3.43 2.75 vs. 3.43
 Fatal bleeding 0.19 vs. 0.33 0.23 vs. 0.33 0.2 vs. 0.5 NR (34 vs. 55 patients) 0.13 vs. 0.38 0.21 vs. 0.38
 ICH 0.23 vs. 0.76 0.32 vs. 0.76 0.5 vs. 0.7 0.33 vs. 0.80 0.26 vs. 0.85 0.39 vs. 0.85
 Major GI bleeding 1.36 vs. 1.25 1.85 vs. 1.25 3.2 vs. 2.2 0.76 vs. 0.86 0.82 vs. 1.23 1.51 vs. 1.23
 Major or NMCR bleeding 14.66 vs. 18.23b,e 16.45 vs. 18.23b,e 14.9 vs. 14.5f 4.07 vs. 6.01 7.97 vs. 13.02 11.10 vs. 13.02
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significantly higher rates of persistence at 1-year follow-up 
or significantly higher adherence (percentage of patients 
who had a proportion of days covered ≥80% during their 
follow-up) than with the use of the twice-daily medication 
dabigatran [37, 96]. A Danish nationwide cohort study in 
approximately 3000 patients with non-valvular AF reported 
that over 75% of patients treated with dabigatran adhered 
to therapy more than 80% of the time (as measured by 
proportion of days covered) [57]. Published data on real-
life adherence with edoxaban and apixaban are not yet 
available.
In the phase III studies (across various follow-up peri-
ods), discontinuation rates were: significantly lower with 
apixaban compared with warfarin in ARISTOTLE; simi-
lar between rivaroxaban and warfarin in ROCKET AF and 
between edoxaban and warfarin in ENGAGE-AF; but sig-
nificantly higher with dabigatran compared with warfarin 
in RE-LY, mainly owing to dyspepsia [32, 52, 58, 102]. 
VKA discontinuation rates in real-life practice range 
from 25 to 38% at 1-year follow-up and are higher than 
those reported in controlled phase III studies (10–35% 
over a median follow-up period of 1.8–2.8  years) [13, 
32, 52, 58, 95, 102, 109]. In an analysis of data collected 
from patients with AF in the Dresden NOAC Registry, 
discontinuation rates with dabigatran (25.8% per year) 
were similar to those observed with VKAs in daily prac-
tice, whereas discontinuation rates with rivaroxaban ther-
apy (13.6% per year) were much lower than those with 
VKA therapy [12, 15]. Persistence probabilities at 1 year 
were 53.1, 47.3 and 25.5% with rivaroxaban, dabigatran 
and VKA, respectively, and adherence with a high medi-
cation possession ratio (≥80%) was 61.4% for rivaroxa-
ban and 49.5% for dabigatran [14]. Together, real-life 
data suggest that, in the long-term, patients receiving 
DOACs have better protection against stroke or systemic 
embolism than patients receiving a VKA.
In the US, 33–69% of all medication-related hospi-
tal admissions are estimated to be attributable to poor 
medication adherence, with the resulting costs of non-
adherence being approximately $100  billion/year [100, 
115]. An analysis of adverse events based on hospital 
data identified warfarin as a medication that was most 
commonly implicated in hospitalization of adults aged 
≥65 years (33.3%) owing to adverse drug effects [24].
Table 4  Subgroup analyses from the phase III clinical trials of direct oral anticoagulants for prevention of stroke in patients with non-valvular 
atrial fibrillation (there are currently no subgroup analyses of ENGAGE AF data available for subgroups specified in the table)
Statistically significant values (p ≤ 0.05) are given in bold
CrCl creatinine clearance, HF heart failure, HF-pEF heart failure with preserved ejection fraction, HF-LVSD heart failure caused by left ven-
tricular systolic dysfunction, MI myocardial infarction, NR not reported, SE systemic embolism
a Values are for CrCl <50 mL/min. bValues are for CrCl ≤50 mL/min. cValues are for coronary artery disease defined as documented coronary 
artery disease, history of MI and/or history of coronary revascularization
RE-LY subgroups
(Dabigatran vs. warfarin)





110 mg bid; 150 mg bid [43]
≥75 years [60] ≥75 years [61]
 Stroke or SE 1.89 vs. 2.14 1.43 vs. 2.14 2.29 vs. 2.85 1.56 vs. 2.19
 Major bleeding 4.43 vs. 4.37 5.10 vs. 4.37 4.86 vs. 4.40 3.33 vs. 5.19
CrCl 30–50 mL/min [68] [50] [69]
 Stroke or SE 2.32 vs. 2.70a 1.53 vs. 2.70a 2.32 vs. 2.77 2.11 vs. 2.67b
 Major bleeding 5.45 vs. 5.49a 5.50 vs. 5.49a 4.49 vs. 4.70 3.21 vs. 6.44b
Diabetes [21] [10] [45]
 Stroke or SE 1.76 vs. 2.35 1.46 vs. 2.35 1.89 vs. 2.33 1.39 vs. 1.86
 Major bleeding 3.81 vs. 4.19 4.66 vs. 4.19 3.79 vs. 3.90 3.01 vs. 3.13
HF [49] [120] [87]
 Stroke or SE 1.90 vs. 1.92 1.44 vs. 1.92 1.90 vs. 2.09 0.99 vs. 1.80 [HF-LVSD]
1.51 vs. 1.54 [HF-pEF]
 Major bleeding 3.26 vs. 3.90 3.10 vs. 3.90 NR 2.77 vs. 3.41 [HF-LVSD]
1.95 vs. 3.17 [HF-pEF]
Prior MI [70] [86] [9]
 Stroke or SE 1.55 vs. 1.93c 1.46 vs. 1.93c 1.42 vs. 2.35 1.47 vs. 1.55c
 Major bleeding 3.94 vs. 4.52c 4.24 vs. 4.52c 4.75 vs. 3.61 2.39 vs. 3.05c
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The true cost of vitamin K antagonist therapy
In addition to treatment effectiveness and safety, cost-effec-
tiveness is another consideration for decision making by 
healthcare professionals who have several therapy options. 
VKAs are often perceived to have lower costs; however, 
although costs for the drug itself are lower when comparing 
with DOACs, the true cost of VKA treatment needs to take 
into account the expenses related to the general management 
of therapy. These include routine coagulation monitoring, 
adverse clinical outcomes during therapy (such as bleeding 
and thromboembolic events) and as a result of non-adherence.
In clinical practice, the estimated mean numbers of 
hospitalization days, outpatient visits and AF-related hos-
pitalizations associated with rivaroxaban are reported to 
be lower than those associated with warfarin [79, 81, 82]. 
Similar published real-world evidence is not yet available 
for apixaban, edoxaban or dabigatran.
A cost-modelling analysis suggests that, based on the 
expected number of thrombotic or bleeding events avoided 
with use of DOACs vs. warfarin, medical costs are reduced 
when DOACs are used instead of warfarin/placebo for the 
prevention of stroke in patients with non-valvular AF or 
for the treatment of VTE [4]. However, a model simula-
tion based on the Slovenian healthcare payer perspective 
using 2014 costs demonstrated that cost-effectiveness of 
the DOACs vs. warfarin is highly sensitive to warfarin anti-
coagulation control [75]. With a TTR of 60%, the probabil-
ity that warfarin was a cost-effective option was unlikely 
(probability 1%). This percentage rises with increasing 
TTR: at a TTR of 70%, warfarin was more cost-effective 
than DOACs in half of the simulations [75].
Reversal of anticoagulant effect and management 
of bleeding
There is currently limited clinical experience with spe-
cific reversal agents for the DOACs. However, although 
vitamin K is a direct, effective reversal agent for VKAs, a 
normal INR is generally only achieved over approximately 
24 h, which would not help in the case of clinically impor-
tant bleeding events such as intracranial haemorrhage [3, 
84]. Therefore, coagulation factor concentrates need to be 
administered in parallel with vitamin K to restore haemo-
stasis quickly [3, 84, 111].
In most clinical situations, the short half-lives of the 
DOACs obviate the need for reversal, and standard pro-
cedures for bleeding management are normally sufficient 
to control bleeding events [28]. In fact, specific reversal 
agents for DOACs would be very rarely needed in daily 
clinical care. In exceptional clinical situations (such as 
life-threatening bleeding or emergency surgery associated 
with a high bleeding risk), coagulation factor concentrates 
such as prothrombin complex concentrate, activated pro-
thrombin complex concentrate or recombinant factor VIIa 
may be considered [11, 20, 22, 38]. However, there is lim-
ited clinical experience with these agents in patients with 
bleeding events. Haemostatic agents such as prothrom-
bin complex concentrate or recombinant factor VIIa may 
increase the risk of thromboembolism if they are admin-
istered when the plasma concentration of the anticoagu-
lant is low [124]. Therefore, the risk with the use of these 
agents has to be balanced with their potential for bleeding 
control. Recent months have seen the clinical approval 
of idarucizumab, a specific reversal agent for dabigatran, 
based on results of a phase III study [104, 105] (Table 5). 
Moreover, results with a specific reversal agent, andexa-
net alfa (http://www.clinicaltrials.gov, NCT02220725 
and NCT02329327) for factor Xa inhibitors have shown 
that it has the potential to quickly and effectively reverse 
the anticoagulation effect of rivaroxaban and apixaban 
[113]. Andexanet alfa is expected to be approved in 2017 
[107]. PER977 (Perosphere) is being assessed as a rever-
sal agent for edoxaban in clinical trials with promising 
preliminary results [7, 35] (http://www.clinicaltrials.gov, 
NCT02207257).
Table 5  Reversal agents for DOACs
DOAC direct oral anticoagulant, EMA European Medicines Agency, FDA US Food and Drug Administration, LMWH low-molecular-weight 
heparin, UFH unfractionated heparin
DOAC Reversal agent, description Approval status References
Dabigatran Idarucizumab (Praxbind®): a fully humanized, monoclonal antibody fragment 
designed to specifically reverse the anticoagulant effect of dabigatran
FDA and EMA [25, 104, 105]
Factor Xa inhibitors (rivaroxa-
ban and apixaban tested)
Andexanet alfa: an inactive, recombinant version of the human factor Xa 






All DOACs, UFH and LMWH PER977: a small, synthetic, water-soluble, cationic molecule that is designed 
to bind specifically to UFH and LMWH through non-covalent hydrogen 
bonding and charge–charge interactions and similarly also binds to edoxa-
ban, rivaroxaban, apixaban and dabigatran
In development [7, 35]
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When to switch and when not to switch 
from vitamin K antagonists to direct oral 
anticoagulants
Patients who have been initiated on VKA therapy can be 
switched to a DOAC (see individual Summary of Product 
Characteristics for further details [11, 20, 22, 38]). This 
switch should be based on a clinical benefit–risk assess-
ment. Specific reasons for switching may include—but are 
not limited to—poor INR control, stroke/systemic embo-
lism or serious bleeding during VKA therapy, poor compli-
ance (e.g. relating to the inconveniences of VKA therapy), 
patient preference to switch to a DOAC therapy, reduced 
long-term costs and fear of bleeding (particularly within 
the fragile patient population). Switching strategies are 
reviewed in the updated practical guide of the European 
Heart Rhythm Association (EHRA) [66].
The effectiveness and safety of switching patients with 
AF from a VKA to DOAC therapy has been demonstrated 
in the Dresden NOAC Registry [17, 90]. Data from this 
registry regarding patients who switched from a VKA to 
rivaroxaban or dabigatran for stroke prevention or VTE 
treatment suggest that the potential for bleeding should be 
monitored carefully in the first few days after the transi-
tion, during which residual VKA activity may remain [90]. 
One study reported that only 75% of VKA patients had an 
INR measurement documented before they were started on 
a DOAC; on average, DOAC was started within 2–5 days 
after the last intake of VKA. At the 30-day follow-up, 
the rates of major cardiovascular events (0.8%; 95% CI 
0.3–1.8) and major bleeding complications (0.3%; 95% CI 
0.0–1.0) were low, with a rate of any bleeding of 12.2% 
(95% CI 9.8–14.8) in patients with and without INR testing 
of the residual VKA effect [17]. A Danish analysis demon-
strated the importance of adherence to the switching proto-
cols outlined in the Summary of Product Characteristics for 
dabigatran [116]. This study evaluated real-world outcomes 
in patients with AF: there was an increased risk of throm-
boembolism and bleeding with dabigatran in previous VKA 
users. The authors of this study cautiously interpreted these 
unexpected results as reflecting patient selection and drug-
switching practices. Dabigatran use in VKA-naïve patients 
was reported to be safe [116]. The EHRA practical guide 
provides a schematic overview of switching protocols from 
a VKA to a DOAC and vice versa and also emphasizes the 
importance of adherence to the established switching strat-
egies [66].
Some patients, especially those with good INR control 
and TTR, may prefer to continue with VKA therapy instead 
of switching to a DOAC. Patients may also benefit from 
continued VKA therapy, including those with contraindi-
cations to DOAC therapy. For example, patients with end-
stage kidney disease (CrCl <15 mL/min) have significantly 
increased risks of stroke and bleeding compared with 
patients with normal kidney function [99]. End-stage kid-
ney disease is also associated with reduced activity of 
cytochrome P450 2C9, leading to lower warfarin dosing 
requirements [41]. Patients with valvular AF as opposed 
to non-valvular AF (particularly in those with mechani-
cal valves) should be treated with a VKA because DOACs 
are not approved in these patients [11, 20, 22, 38]. Moreo-
ver, the outcomes of the RE-ALIGN trial that assessed 
dabigatran vs. warfarin in patients with mechanical valves 
reinforced the recommendations of the current guidelines 
against the use of DOACs in these patients. This trial had 
to be terminated prematurely owing to an excess of throm-
boembolic and bleeding events among patients receiving 
dabigatran (150, 220 or 300 mg twice daily) [42].
Which direct oral anticoagulant for which patient?
In the absence of a head-to-head trial with DOACs (no 
such trial is planned or ongoing), no direct answer can be 
provided to this question. The overall aim should be that 
all patients with AF who are indicated for anticoagulation 
should receive appropriate therapy. As discussed at the 
beginning of this article, a substantial proportion of patients 
with AF who should be receiving anticoagulation are not 
receiving OAC therapy of any form. DOACs—overcom-
ing several of the limitations of VKAs—offer alternative 
and potentially preferred therapy options [27] both in treat-
ment-naïve patients with newly diagnosed AF in need of 
anticoagulation therapy and in patients with AF at risk of 
stroke and systemic embolism who are not receiving appro-
priate therapy or who have poorly controlled VKA therapy.
The choice of which DOAC is the right agent for which 
patient, initially choosing between a direct thrombin inhibi-
tor and factor Xa inhibitor, should be based on the pharma-
cokinetics/pharmacodynamics and integration of the clini-
cal data with respect to the patient’s characteristics. The 
following recommendations, based on the EHRA practical 
guide, can be used for decision making [66]. In patients 
with renal impairment, factor Xa inhibitors (rivaroxaban, 
apixaban or edoxaban) should be preferred over dabigatran. 
Similarly, factor Xa inhibitors have demonstrated no change 
to the benefit–risk profile in elderly patients and in patients 
with a pronounced cardiovascular co-morbidity compared 
with other patient groups (with especially favourable data 
for rivaroxaban [60, 63, 86]). Patients with a history or high 
risk of gastrointestinal bleeding may have a lower risk of 
bleeding complications with apixaban and low-dose edoxa-
ban than with dabigatran, rivaroxaban or high-dose edoxa-
ban; however, dabigatran, rivaroxaban and warfarin may 
have similar rates of gastrointestinal bleeding in real-life 
clinical practice [30]. Furthermore, there is some evidence 
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that patients with a high risk for ischaemic stroke may ben-
efit from a direct thrombin inhibitor (i.e. dabigatran) [108]. 
More data from real-life studies will shed light on which 
agent provides the best benefit–risk ratio for which patient.
Conclusions
The availability of DOACs provides an alternative manage-
ment option for patients with AF, especially when the treat-
ing physician is hesitant to prescribe a VKA owing to the 
associated limitations, such as routine coagulation monitor-
ing and dose adjustments, food and drug interactions and 
concerns about bleeding complications. Overall, currently 
available real-world evidence shows that DOACs have sim-
ilar or improved effectiveness and safety outcomes com-
pared with warfarin. With regards to which DOAC is best 
suited for which patient to maximize safety and effective-
ness, more prospective real-world data are required because 
database studies show divergent outcomes. Overall, recom-
mendations in the EHRA practical guide suggest  actions 
taking into account not only clinically relevant patient char-
acteristics but also patient preferences. Adherence to ther-
apy is an important factor to achieve best outcomes, and 
there is some evidence that patients adhere better to once-
daily medications compared with those taken twice-daily.
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